Jessica Stith, APRN
Nurse Practitioner · la Grange, KYNPI 1427788413
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,464 of the $14,811 with a category attached, or 77.4%. 30 manufacturers reported payments, led by Phathom Pharmaceuticals, Inc. at 31.7% of the total. 2025 is the largest year on record at $6,083, 7.4 times the $820 reported in 2022. Among nurse practitioner clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 791 payments — averaging $18.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phathom Pharmaceuticals, Inc.$5K
- AbbVie$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Johnson & Johnson$2K
- Takeda Pharmaceuticals U.S.A., Inc.$887
- Sanofi$743
- plus $3K from 24 others
What the payments were for
- Speaking & faculty fees$3,29022%
- Food & beverage$11,46477%
- Education$570%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 123 | $4,700 |
| AbbVie | 158 | $2,387 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 135 | $1,619 |
| Johnson & Johnson(2 entities) | 104 | $1,565 |
| Takeda Pharmaceuticals U.S.A., Inc. | 53 | $887 |
| Sanofi | 35 | $743 |
| Ardelyx, Inc. | 53 | $527 |
| Madrigal Pharmaceuticals | 17 | $420 |
| QOL Medical, LLC | 28 | $387 |
| Regeneron Healthcare Solutions, Inc. | 12 | $241 |
| Bristol Myers Squibb | 11 | $227 |
| Intercept Pharmaceuticals, Inc. | 11 | $173 |
| Ipsen Biopharmaceuticals, Inc | 12 | $157 |
| Merck | 10 | $151 |
| Janssen Scientific Affairs, LLC | 1 | $113 |
| Pfizer | 5 | $79 |
| Ironwood Pharmaceuticals, Inc | 3 | $71 |
| Sandoz | 3 | $55 |
| Celltrion USA Inc. | 3 | $55 |
| Albireo Pharma, Inc. | 2 | $39 |
| Aimmune Therapeutics, Inc. | 1 | $33 |
| Organon | 2 | $29 |
| Boehringer Ingelheim | 2 | $29 |
| Gilead | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $18 |
| Lucid Diagnostics Inc. | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Pacira Pharmaceuticals Incorporated | 1 | $14 |
| Braintree Laboratories, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,811 in reported general payments places this provider in the 95th percentile of 1,918 nurse practitioner providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SucraidSacrosidase | 19 | $264,882 |
| LinzessLinaclotide | 143 | $105,232 |
| Dupixent PenDupilumab | 13 | $94,365 |
| XifaxanRifaximin | 34 | $87,880 |
| MovantikNaloxegol Oxalate | 87 | $36,715 |
| VoqueznaVonoprazan Fumarate | 41 | $30,992 |
| Alosetron Hcl | 31 | $24,526 |
| TrulancePlecanatide | 16 | $13,884 |
| Lubiprostone | 122 | $11,919 |
| Colestipol Hcl | 143 | $10,898 |
| Sucralfate | 200 | $10,668 |
| Omeprazole | 674 | $8,358 |
| Pantoprazole Sodium | 381 | $7,168 |
| Mesalamine ErMesalamine | 14 | $6,270 |
| ErythromycinErythromycin Base | 14 | $4,960 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| QOL Medical, LLCSucraid | $387 | $264,88219 claims |
| AbbVieLinzess | $2,387 | $105,232143 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $1,619 | $101,76550 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $4,700 | $30,99241 claims |
| SandozLansoprazole | $55 | $1,03825 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,918 nurse practitioner providers in Kentucky.
Other nurse practitioner in la Grange
- Rachael BradfordLexington$447K
- Tara MuddLouisville$243K
- Lee HaasLouisville$95K
- Ashley KnableLouisville$86K
- Christina BenningerLouisville$81K
- Courtney BowlingCampbellsville$47K
- Rebecca BraunerLouisville$40K
- Scott SeitzWinchester$34K
- Kristen KreinestEdgewood$34K
- Lillian ArgentEdgewood$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.